TY - JOUR
T1 - Volumetric analysis of 18F-FDG PET in glioblastoma multiforme
T2 - Prognostic information and possible role in definition of target volumes in radiation dose escalation
AU - Tralins, Kevin S.
AU - Douglas, James G.
AU - Stelzer, Keith J.
AU - Mankoff, David A.
AU - Silbergeld, Daniel L.
AU - Rostomilly, Robert
AU - Hummel, Sharon
AU - Scharnhorst, Jeff
AU - Krohn, Kenneth A.
AU - Spence, Alexander M.
PY - 2002/12/1
Y1 - 2002/12/1
N2 - The use of 18F-FDG PET for brain tumors has been shown to be accurate in identifying areas of active disease. Radiation dose escalation in the treatment of glioblastoma multiforme (GBM) may lead to improved disease control. On the basis of these premises, we initiated a pilot study to investigate the use of 18F-FDG PET for the guidance of radiation dose escalation in the treatment of GBM. Methods: Patients were considered eligible to participate in the study if they had a diagnosis of GBM, were at least 18 y old, and had a score of at least 60 on the Karnofsky Scale. Patients were treated with standard conformal fractionated radiotherapy (1.8 Gy per fraction, to 59.4 Gy), with volumes defined by MRI. At a dose of 45-50.4 Gy, patients underwent 18F-FDG PET for boost target delineation. Final noncoplanar fields (3-4) were designed to treat the volume of abnormal 18F-FDG uptake plus a 0.5-cm margin for an additional 20 Gy (2 Gy per fraction), to a total dose of 79.4 Gy. If no abnormal 18F-FDG uptake was observed, treatment was stopped after the conventional course of 59.4 Gy. Age, Karnofsky score, MRI-based volumes, and 18F-FDG PET volume were analyzed as prognostic variables for time to tumor progression (TTP) and overall survival. 18F-FDG PET volumes and MRI-based volumes were compared to assess concordance. Results: For the 27 patients who could be evaluated, median actuarial TTP was 43 wk, and median actuarial survival was 70 wk. On univariate analysis, 18F-FDG PET, T1-weighted MRI gadolinium enhancement (excluding nonenhancing resection cavity), and T2-weighted MRI volumes were significantly predictive of TTP. On multivariate analysis, only 18F-FDG PET volume retained significance for predicting TTP. Similar results were obtained on analysis of these variables as prognostic factors for survival. When 18F-FDG PET-based volumes were compared with MRI-based volumes, a difference of at least 25% was detected in all patients, with all but 2 having smaller 18F-FDG PET volumes. Of patients in whom 18F-FDG uptake was initially present but treatment subsequently failed, 83% demonstrated the first tumor progression within the region of abnormal 18F-FDG uptake. Conclusion: In comparison with MRI, 18F-FDG PET defined unique volumes for radiation dose escalation in the treatment of GBM. 18F-FDG PET volumes were predictive of survival and time to tumor progression in the treatment of patients with GBM.
AB - The use of 18F-FDG PET for brain tumors has been shown to be accurate in identifying areas of active disease. Radiation dose escalation in the treatment of glioblastoma multiforme (GBM) may lead to improved disease control. On the basis of these premises, we initiated a pilot study to investigate the use of 18F-FDG PET for the guidance of radiation dose escalation in the treatment of GBM. Methods: Patients were considered eligible to participate in the study if they had a diagnosis of GBM, were at least 18 y old, and had a score of at least 60 on the Karnofsky Scale. Patients were treated with standard conformal fractionated radiotherapy (1.8 Gy per fraction, to 59.4 Gy), with volumes defined by MRI. At a dose of 45-50.4 Gy, patients underwent 18F-FDG PET for boost target delineation. Final noncoplanar fields (3-4) were designed to treat the volume of abnormal 18F-FDG uptake plus a 0.5-cm margin for an additional 20 Gy (2 Gy per fraction), to a total dose of 79.4 Gy. If no abnormal 18F-FDG uptake was observed, treatment was stopped after the conventional course of 59.4 Gy. Age, Karnofsky score, MRI-based volumes, and 18F-FDG PET volume were analyzed as prognostic variables for time to tumor progression (TTP) and overall survival. 18F-FDG PET volumes and MRI-based volumes were compared to assess concordance. Results: For the 27 patients who could be evaluated, median actuarial TTP was 43 wk, and median actuarial survival was 70 wk. On univariate analysis, 18F-FDG PET, T1-weighted MRI gadolinium enhancement (excluding nonenhancing resection cavity), and T2-weighted MRI volumes were significantly predictive of TTP. On multivariate analysis, only 18F-FDG PET volume retained significance for predicting TTP. Similar results were obtained on analysis of these variables as prognostic factors for survival. When 18F-FDG PET-based volumes were compared with MRI-based volumes, a difference of at least 25% was detected in all patients, with all but 2 having smaller 18F-FDG PET volumes. Of patients in whom 18F-FDG uptake was initially present but treatment subsequently failed, 83% demonstrated the first tumor progression within the region of abnormal 18F-FDG uptake. Conclusion: In comparison with MRI, 18F-FDG PET defined unique volumes for radiation dose escalation in the treatment of GBM. 18F-FDG PET volumes were predictive of survival and time to tumor progression in the treatment of patients with GBM.
KW - Glioblastoma multiforme
KW - PET
KW - Radiation dose escalation
UR - http://www.scopus.com/inward/record.url?scp=0036882162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036882162&partnerID=8YFLogxK
M3 - Article
C2 - 12468518
AN - SCOPUS:0036882162
SN - 0161-5505
VL - 43
SP - 1667
EP - 1673
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 12
ER -